Scope and claims of U.S. Patent 11,278,622: ceftolozane sulfate/tazobactam for nosocomial pneumonia with impurity limits and stability conditions
U.S. Patent 11,278,622 is drafted as a use claim (method of treating) tied to (i) the indication (nosocomial pneumonia; hospital-acquired and ventilator-associated), (ii) the drug substance composition (ceftolozane sulfate + tazobactam sodium in a 2:1 w/w active ratio), and (iii) tight impurity/related-substance control for specific degradation/impurity species (compound of formula (III), compound of formula (IV), and a compound defined by mass spectra in FIG. 14), measured by HPLC at 254 nm after defined accelerated/controlled storage as a solid (25°C/60% RH for 1 month for formula (III) and for 3 months for formula (IV)). The enforceable perimeter is therefore narrow: medical use is only infringing when the administered product meets the specific impurity thresholds after the stated solid-state stability conditions.
Independent claim set (your text) is a family of three overlapping claim “scopes”:
- Claims 1–13: Nosocomial pneumonia method using ceftolozane/tazobactam (2:1 w/w) where compound (III) is <0.15% after 1 month solid storage at 25°C/60% RH; dependent claim carve-outs narrow impurity (<0.1%, <0.03%), dosage (2,000 mg/1,000 mg), unit dosage, and administration route (parenteral/IV infusion).
- Claims 14–18: Same indication and ratio, but extends stability window to 3 months and adds compound (IV) impurity limit (<1.5% after 3 months); dependent claims mirror the hospital acquired/ventilator associated subgroup and a further tighter impurity (formula (III) <0.05% after 3 months).
- Claims 19–31: Same concept but replaces formula-(III)/(IV) definitions with a mass-spectra-defined impurity (FIG. 14 compound) and retains the same HPLC 254 nm measurement and solid storage limits: <0.15% after 1 month for FIG. 14 compound; and <0.15% plus <1.5% for FIG. 14 compound and formula (IV) after 3 months (as written in your text, claims 28–31 contain both FIG. 14 and formula (IV) limits).
This claim architecture is typical of patents aimed at manufacturing-process and formulation control (impurities and stability) presented as product-conditioned medical use.
What exactly do the claims require to infringe?
Which drug product composition is required?
All presented claims require:
- Active ingredients: ceftolozane sulfate and tazobactam sodium
- Active ratio: 2:1 by weight between ceftolozane active and tazobactam active
- Dosage strength carve-out (only in dependent claims): ceftolozane 2,000 mg / tazobactam 1,000 mg (claims 6, 8, 24, 26)
What indication triggers infringement?
- Independent claim nucleus: “infection … which is a nosocomial pneumonia infection in a human patient”
- Dependent narrowing:
- Hospital acquired bacterial pneumonia (claims 2, 15, 20, 29)
- Ventilator-associated bacterial pneumonia (claims 3, 16, 21, 30)
What impurity/species limits and stability conditions are required?
The infringement condition is the product quality after solid storage and measured by a defined analytical method.
Claim 1 (formula III impurity after 1-month solid storage)
- Product must comprise ceftolozane/tazobactam (2:1 w/w) and have:
- <0.15% compound of formula (III) relative to ceftolozane sulfate
- measured by HPLC at 254 nm
- when stored as a solid for 1 month at 25°C and 60% RH
Claim 4 and 5 tighten formula (III)
- Claim 4: <0.1% after same 1-month/25°C/60% RH/HPLC254
- Claim 5: <0.03% after same conditions
Claim 14 (formula III after 3 months + formula IV added)
- When stored as solid for 3 months at 25°C/60% RH:
- <0.15% compound (III) relative to ceftolozane sulfate (HPLC254)
- and <1.5% compound (IV) relative to ceftolozane sulfate (HPLC254)
Claim 17 tightens formula (III) after 3 months
- <0.05% after 3 months storage
Claims 19–23 and 28–31 tie to the “FIG. 14” compound by mass spectra
- Claim 19:
- <0.15% (relative to ceftolozane sulfate) of “compound having a mass spectra depicted in FIG. 14”
- measured by HPLC 254 nm
- after 1 month solid storage at 25°C/60% RH
- with 2:1 w/w ratio
- Claims 22 and 23:
- <0.1% and <0.03% respectively after same 1-month storage
- Claim 28:
- after 3 months solid storage:
- <0.15% of the FIG. 14 compound
- and <1.5% of compound of formula (IV)
What administration and dosage form are claimed?
- Independent and some dependent claims are method-of-treatment regardless of route, but your text includes route limitations:
- Parenteral administration (claim 9)
- IV infusion (claims 10–13; 11–13 depend on hospital acquired/ventilator-associated subtypes; claim 27; claim 31)
- Unit dosage form appears as dependent claims:
- unit dosage (claims 7, 8, 25, 26)
Practical reading: In most infringement analyses, the pivotal issues are (i) whether the asserted product matches 2:1 w/w ceftolozane/tazobactam, (ii) whether the product’s measured impurity profile after solid-state storage meets the exact numeric thresholds for the specified impurity definitions, and (iii) whether the prescription is for the claimed nosocomial pneumonia subpopulation. Route/date formulation constraints become secondary unless a defendant’s use case is designed around them.
How broad is the claim estate vs. typical ceftolozane/tazobactam patents?
Is this protecting a mechanism-of-action or a medical regimen?
No. The claims are not drafted around dosing schedules, duration, or patient-specific pharmacology. They are drafted around:
- Indication category (nosocomial pneumonia; hospital-acquired; ventilator-associated)
- Product quality definition (impurity percentages under controlled storage and a specified analytical method)
- Active ratio (2:1 w/w)
This makes the estate more akin to a formulation/impurity control patent presented as use.
Where is the boundary between “infringing composition” and “non-infringing composition”?
The numeric impurity cutoffs are the boundary. A design-around strategy typically targets:
- lower impurity formation during storage (reduced presence of the claimed species)
- analytical method/acceptance criteria mapping (though infringement uses the claim’s HPLC 254 nm method)
- alternative storage conditions or different solid-state form that does not meet the “when stored as a solid” condition (depending on how the court construes “as a solid for 1 month at 25°C/60% RH” in context of the product’s packaging and label storage instructions)
Are the formula-(III)/(IV) and FIG.-14 compound the same impurity?
Your text uses three distinct definitions:
- compound of formula (III)
- compound of formula (IV)
- compound defined by mass spectra in FIG. 14
The claim set suggests FIG. 14 compound may be the same as formula (III) (because claims 19–23 mirror the same impurity thresholds and 1-month window as claims 1, 4, 5) but the text does not confirm identity. The patent’s internal consistency implies claim coverage is expanded by alternative definitions of the same (or related) impurity.
What is the practical scope of claims 1–31?
Infringing scenario (high confidence by claim language)
A defendant’s product infringes if:
- The product contains ceftolozane sulfate + tazobactam sodium at 2:1 w/w active ratio, and
- The product, when stored as a solid at 25°C/60% RH for 1 month (for formula III / FIG. 14) or 3 months (for formula IV plus formula III window in claim 14/28), has impurity levels meeting the specified thresholds by HPLC 254 nm, and
- A clinician treats a patient with nosocomial pneumonia (and in dependent claims, hospital-acquired or ventilator-associated), using that product.
Non-infringing scenario (high confidence by claim language)
Non-infringement follows if any required element fails:
- active ratio deviates from 2:1 w/w
- the claimed impurity exceeds the threshold (e.g., formula (III) ≥0.15% after 1 month)
- the specified impurity definition is not present or is below threshold
- the therapeutic use is outside the nosocomial pneumonia category (for dependent claims)
- route limitations are imposed (depending on the asserted claim)
How do the dependent claims expand claim coverage?
Impurity tightening (strongest leverage)
- Claims 4 and 5: <0.1% and <0.03% for formula (III)
- Claim 17: <0.05% for formula (III) after 3 months
- Claims 22 and 23: <0.1% and <0.03% for FIG. 14 compound after 1 month
These create tiers that can be valuable in litigation because an accused product might satisfy <0.15% but not satisfy tighter limits; asserting the highest-matching tier can improve enforcement odds.
Sub-indication specificity
- Hospital-acquired and ventilator-associated subsections narrow dependent claims. This supports enforcement against prescribing patterns and promotional labeling positions.
Administration route as an additional constraint
- IV infusion constraints appear in dependent claims. If a competitor’s label or administered route differs (or if the litigation asserts those dependent claims), route could become a contested element.
Dose/strength and unit dose claims (limited but present)
- The 2,000 mg/1,000 mg and unit dosage dependent claims narrow coverage to a specific strength format.
How strong is the patent landscape coverage implied by the impurity-and-stability claim design?
What this structure typically targets in Paragraph IV or design-around disputes
These claim elements are commonly used to attack:
- generic formulations where impurity profile differs from reference listed drug acceptance ranges or from the patent’s own impurity thresholds under defined storage
- manufacturing changes that increase formation of a specific related substance during storage
The “method of treating” wrapper can still enable enforcement because the infringement requires the administered product’s impurity characteristics to match the claimed thresholds at specific storage conditions.
Litigation posture likely to focus on:
- mapping the defendant product’s impurity species to formula (III), formula (IV), and/or the FIG. 14 compound defined by mass spectra
- reproducing the claim-specific stability test conditions:
- solid storage, 25°C, 60% RH, 1 month or 3 months
- HPLC method at 254 nm
- establishing whether the prescribed/used indication fits:
- nosocomial pneumonia
- hospital-acquired vs ventilator-associated
Claim-chart logic (what each element would map to in enforcement)
| Claim element (core) |
What must be shown for infringement |
| Nosocomial pneumonia method in a human |
Use/labeling/prescribing for nosocomial pneumonia; dependent subtypes if asserted |
| Administer ceftolozane sulfate + tazobactam sodium |
Evidence that accused product contains both and is administered as claimed |
| Active ratio 2:1 w/w |
Formulation composition and assay verifying ratio |
| Impurity definition (formula III / formula IV / FIG. 14 compound) |
Analytical identification that the impurity corresponds to the claimed species |
| Impurity limit numeric cutoff |
HPLC quantified percentage relative to ceftolozane sulfate |
| “When stored as a solid for X months at 25°C/60% RH” |
Stability study replicating the claimed storage conditions for the accused product |
| HPLC at 254 nm |
Analytical method conditions and wavelength match |
Key takeaways
- U.S. Patent 11,278,622 is not a broad “ceftolozane/tazobactam treats pneumonia” patent. It is a product-condition medical use patent: infringement depends on impurity levels (formula (III), formula (IV), and a FIG. 14 compound) after defined solid-state storage measured by HPLC 254 nm, plus a 2:1 w/w active ratio and nosocomial pneumonia use.
- The strongest enforceable lever is the numeric impurity thresholds under the specified storage windows (1 month for formula (III)/FIG. 14; 3 months for formula (IV) with formula (III)).
- The dependent claims create multiple litigation entry points: tighter impurity tiers, hospital-acquired vs ventilator-associated subtypes, strength (2,000 mg/1,000 mg), and IV infusion route.
FAQs
1) What impurities does U.S. Patent 11,278,622 monitor for infringement?
It monitors three species: a compound of formula (III), a compound of formula (IV), and a compound defined by mass spectra in FIG. 14, each quantified by HPLC at 254 nm and constrained by specific numeric limits.
2) Do the claims require a specific dosing duration or regimen?
No. The claim text provided focuses on method of treating nosocomial pneumonia via administering the specified composition meeting impurity and ratio criteria; it does not set a dosing duration in the provided claims.
3) What is the storage condition that controls whether a product infringes?
The claims require that the composition, when stored as a solid at 25°C and 60% RH, meets impurity limits after 1 month (for formula (III)/FIG. 14) and after 3 months (for formula (IV) and the extended formula (III) window).
4) Can a generic avoid infringement by meeting only the <0.15% impurity threshold?
It may avoid infringement of narrower tiers but could still fall within broader claims that use <0.15% thresholds. Dependent claims add tighter limits (<0.1%, <0.05%, <0.03%), so matching the broad cutoff alone does not guarantee freedom.
5) Does the patent cover both hospital-acquired and ventilator-associated pneumonia?
Yes through dependent claim structure: hospital-acquired is recited in multiple dependent claims and ventilator-associated is also recited, each narrowing the infection type.
References
No external sources were provided in the prompt, and no patent text beyond your supplied claims/summary was included. Therefore, no citations can be generated from the provided material.
